Back to Authors

Rosenwald, Andreas

https://orcid.org/0000-0001-7282-8374

A5028397596 | I25974101

Mayo Clinic

University of Würzburg

Citations 31

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Blood | July 14, 2016 | Volume: 128 | Issue: 8 | Pages: 1112-1120

10.1182/blood-2016-05-717355 | PMID 27418643

Key Points The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.